Previous Close | 1.2620 |
Open | 1.2180 |
Bid | 1.1980 x 0 |
Ask | 1.2060 x 0 |
Day's Range | 1.1800 - 1.2500 |
52 Week Range | 0.3500 - 1.5680 |
Volume | |
Avg. Volume | 1,128,740 |
Market Cap | 924.04M |
Beta (5Y Monthly) | 1.35 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2500 |
Earnings Date | Oct 24, 2024 - Oct 28, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.13 |
Despite a decline in net sales, Alligator Bioscience AB (FRA:7AL) showcases promising clinical developments and strategic partnerships.
Early Data Indicate Clinical Activity in Patients with Multiple Solid Tumor Types Prolonged stable disease lasting >11 months demonstrated in Breast Cancer Patient Favorable Pharmacokinetics, Safety and Tolerability Observed Data Presented at the ...